Embrella Cardiovascular, Inc. Completes Series A Financing of 2.3 Million Dollars

MALVERN, Pa.--(BUSINESS WIRE)--Embrella Cardiovascular, Inc. today announced that it has completed its initial round of funding, raising 2.3 million dollars.

“It is our belief that Embrella Cardiovascular will change the standard of care for performing a variety of endovascular procedures of the heart and thoracic aorta by significantly reducing the risk of stroke currently associated with these procedures.”

Included in this round of financing were: The “MedFocus Funds,” Irvine, CA; BioStar Fund, Petoskey, MI; and Zeke, LP, Berwyn, PA. Also included in this round were the founders and Angel Investors.

Embrella’s Chairman and co-founder, Jeffrey F. O’Donnell commented, “It is our belief that Embrella Cardiovascular will change the standard of care for performing a variety of endovascular procedures of the heart and thoracic aorta by significantly reducing the risk of stroke currently associated with these procedures.”

O’Donnell further commented, “We are grateful to the early stage investors and our individual investors for their participation in this initial round of funding. Embrella’s Board is focused on accelerating the design and developmental phase of its device and committed to recruiting the brightest and best to ensure success.”

Embrella’s inventor and co-founder, Dr. Judith Carpenter notes, “We are extremely excited about the Embrella device and its potential to prevent embolic strokes and thus decrease the morbidity and mortality rates of patients undergoing cardiovascular procedures. We have made great progress in design thus far and will now accelerate the product development.”

About Embrella

Embrella Cardiovascular, Inc., based in Malvern, Pennsylvania, is an early stage company dedicated to developing a unique, proprietary system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures.